(An active ingredient is what makes a drug work.) Keytruda is a biologic medication. A biologic is made from parts of living organisms. It’s available only as a brand-name drug. Keytruda isn’t ...

BioNTech adds bispecific candidate, mRNA delivery startup as cancer work takes center stage The opportunity is enormous: ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

Keytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight cancer. In India, its high cost limits access. With patents expiring soon, ...

If you're patient, these businesses have a lot of promising projects in the works. Much to the chagrin of investors ... Merck ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

South Korea’s Celltrion has started work on a biosimilar version of pembrolizumab, Merck & Co’s blockbuster immunotherapy Keytruda. The PD-1 checkpoint inhibitor cancer treatment is fast ...

Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...

Dow has been struggling to grow for several quarters. Keytruda now makes up close to half of Merck's revenue. As you can see ...